On day 1, headache, vomiting, neck stiffness, and partial left seizures on the left side developed. Also exhibited were consciousness depression (Glasgow Coma Scale 12 points), hyperrefl exia, and bilateral Babinski sign. A cerebrospinal fl uid (CSF) sample was negative for bacteria in cultures. An electroencephalogram showed diffuse brain suffering. The patient was brought to the intensive care unit with a clinical diagnosis of viral encephalitis. Over the next 24-36 hours, intracranial hypertension developed, and medical treatment was given (sedation, hyperventilation, mannitol, and barbiturates). Conscience depression progressed to a deeper level, and a computed tomography scan of the brain showed dilatation of the temporal ventricles and compression of the peritroncal and sylvian cisterns. During the next 48 hours, the coma level went deeper, reaching 6 on the Glasgow Scale. Another CSF specimen was taken, and PCR results were negative for herpesvirus and enterovirus. Glasgow Coma Scale level was 3 on April 15, and a decompressive craniectomy was done. Seventy-two hours after admission, the patient died. The patient's plasma and CSF were tested for antibodies to dengue and West Nile viruses (immunoglobulin M and G) through ELISA (Focus Technologies, Cypress, CA, USA) and for St. Louis encephalitis and dengue virus by M antibody-capture-ELISA (5). RNA was extracted from plasma and CSF, followed by a generic nested reverse transcription-PCR (RT-PCR) for fl aviviruses (6) . Serologic and molecular test results were negative for the above-mentioned pathogens. Then we performed a generic nested RT-PCR (7), which amplifi es 448 bp at fi rst round and 195 bp (second round) of the alphavirus NSP4 gene. Also, a heminested PCR was done (products 372 bp and 303 bp); RNA from Venezuelan equine encephalitis virus Tc-83 (provided by M. Contigiani, Universidad de Córdoba) was used as positive control. The target region is informative enough to allow the precise identifi cation of the most relevant alphaviruses by sequencing and phylogenetic analysis. Alphavirus genome amplifi cation was achieved for the CSF specimen collected at admission to the hospital. Plasma and a second CSF specimen were PCR negative. To confi rm these fi ndings, another nested RT-PCR reaction targeting the NSP1 gene was done as described previously (8) . A 208-bp amplicon, which corresponded to the expected size for WEEV, was obtained from plasma and the fi rst CSF specimen. Sequence analyses were conducted on the NSP4 fragments. Maximum likelihood (9) and Bayesian (10) phylogenetic analyses gave similar results. The Figure, horses and 1 from Cx. tarsalis mosquitoes. Notably, our sequence is distantly related to GQ287646, which was isolated from Culex spp. mosquitoes in Chaco, Argentina. The nucleotide sequence of the positive control VEEV-Tc83 is correctly placed in the VEEV clade.
Clinical and laboratory fi ndings showed that the illness described here was compatible with viral encephalitis. Using a generic RT-PCR assay on an early CSF sample, we amplifi ed a partial sequence (NSP4 gene) of an alphavirus. Phylogenetic analyses showed that the patient's sequence grouped with sequences from WEEV, with high statistical support. A second RT-PCR assay on the NSP1 gene enabled us to obtain an amplifi cation of 208 bp, which is consistent with the expected size for WEEV. Therefore, we concluded that the fatal disease was likely caused by WEEV. Since the 1970s, to our knowledge, the presence of WEEV (or other alphaviruses) in Uruguay has not been documented. Moreover, no recent reports have been made of genome detection of WEEV in encephalitis cases in the region.
Although the case described here may be rare, the etiology of many viral encephalitides in Uruguay remains unknown. Serologic studies in horses and studies to detect arboviruses in mosquito populations are being conducted to investigate the status of arbovirus infections in Uruguay.
Widespread

Availability of Artemisinin Monotherapy in the United States
To the Editor: Artemisininbased combination therapies are recommended as fi rst line treatments for Plasmodium falciparum malaria in most areas of the world. The article by Shahinas et al. (1) describes a patient who had P. falciparum malaria after returning from Nigeria. Her isolate had an elevated 50% inhibitory concentration to artemisinin derivatives. She had obtained artesunate in Nigeria and took it weekly for malaria prophylaxis, which might have contributed to the relative resistance found.
In 2009, one artemisinin-based combination therapy (artemether/ lumefantrine) became available for use in the United States. However, it is not widely appreciated that artemisinin is actually available in the United States as an herbal supplement for over-thecounter purchase (2) . It is marketed for general health maintenance and for treatment of parasitic infections and cancers (Figure) , although as with other supplements it is not intended to diagnose, treat, cure, or prevent any disease. As in the patient described by Shahinas et al., widespread use
